Short-duration splice promoting compound enables a tunable mouse model of spinal muscular atrophy.

Abstract excerpt

Spinal muscular atrophy (SMA) is a motor neuron disease and the leading genetic cause of infant mortality. SMA results from insufficient survival motor neuron (SMN) protein due to alternative splicing. Antisense oligonucleotides, gene therapy and splicing modifiers recently received FDA approval. Although severe SMA transgenic mouse models have been beneficial for testing therapeutic efficacy, models mimicking...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Animals, Newborn
• Share to Kaplan-Meier Estimate